Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE / AES Joint Translational Task Force
Epilepsia · 2023-11 · 64 (11) · 2891-2908
DOI: 10.1111/epi.17751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, online erschienen am 07.09.2023. Verfasst von Stéphane Auvin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut Universitaire de France, Paris, France. Hauptthemen laut MEDLINE: Epilepsy, Drug Resistant Epilepsy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NICHD NIH HHS, American Epilepsy Society.
Abstract (Originalsprache)
Despite progress in the development of anti‐seizure medications (ASMs), one third of people with epilepsy have drug‐resistant epilepsy (DRE). The working definition of DRE, proposed by the International League Against Epilepsy (ILAE) in 2010, helped identify individuals who might benefit from presurgical evaluation early on. As the incidence of DRE remains high, the TASK1 workgroup on DRE of the ILAE/American Epilepsy Society (AES) Joint Translational Task Force discussed the heterogeneity and complexity of its presentation and mechanisms, the confounders in drawing mechanistic insights when testing treatment responses, and barriers in modeling DRE across the lifespan and translating across species. We propose that it is necessary to revisit the current definition of DRE, in order to transform the preclinical and clinical research of mechanisms and biomarkers, to identify novel, effective, precise, pharmacologic treatments, allowing for earlier recognition of drug resistance and individualized therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut Universitaire de France, Paris, France.
- Paediatric Neurology, Assistance Publique - Hôpitaux de Paris, EpiCARE ERN Member, Robert-Debré Hospital, Paris, France.
- University Paris-Cité, Paris, France.
- Saul R. Korey Department of Neurology, Isabelle Rapin Division of Child Neurology, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, and Montefiore/Einstein Epilepsy Center, Bronx, New…
- Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA.
- Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University (LMU), Munich, Germany.
ORCID-Profile: Stéphane Auvin, Aristea S Galanopoulou, Solomon L Moshé, Heidrun Potschka, Luisa Rocha, Matthew C Walker
Förderung
- NINDS NIH HHS
- NICHD NIH HHS
- American Epilepsy Society
- Consejo Nacional de Ciencia y Tecnología
- Defense Human Resources Activity
- Deutsche Forschungsgemeinschaft
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Institut Universitaire de France
Zitieren
APA
Auvin, S., Galanopoulou, A. S., Moshé, S. L., Potschka, H., Rocha, L., Walker, M. C., & TASK1 workgroup on drug-resistant epilepsy of the ILAE/AES Joint Translational Task Force (2023). Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE / AES Joint Translational Task Force. Epilepsia, 64(11), 2891-2908. https://doi.org/10.1111/epi.17751
Vancouver
Auvin S, Galanopoulou AS, Moshé SL, Potschka H, Rocha L, Walker MC, et al. Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE / AES Joint Translational Task Force. Epilepsia. 2023;64(11):2891-2908. doi:10.1111/epi.17751
BibTeX
@article{Auvin2023,
author = {Auvin, Stéphane and Galanopoulou, Aristea S and Moshé, Solomon L and Potschka, Heidrun and Rocha, Luisa and Walker, Matthew C and TASK1 workgroup on drug-resistant epilepsy of the ILAE/AES Joint Translational Task Force, TASK1 workgroup on drug-resistant epilepsy of the ILAE/AES Joint Translational Task Force},
title = {Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE / AES Joint Translational Task Force},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {11},
pages = {2891--2908},
doi = {10.1111/epi.17751}
}
EUVIMED